Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma

World Journal of Gastroenterology

Volumn 17, Issue 47, 2011, Pages 5221-5226

  Gao, She Gan ^a   Jia, Rui Nuo ^a   Feng, Xiao Shan ^a   Xie, Xuan Hu ^a   Shan, Tan You ^a   Pan, Li Xian ^a   Song, Na Sha ^a   Wang, Yu Feng ^a   Ding, Kai Li ^a   Wang, Li Dong ^b  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Gastric cardiac adenocarcinoma; Oxaliplatin; S 1; Treatment effect

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DYSPHAGIA; FATIGUE; FEMALE; FEVER; GASTRIC CARDIAC ADENOCARCINOMA; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; SWALLOWING; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 83755196620     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i47.5221     Document Type: Article

References (26)

1. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15: 1773-1781
2. Wang DL, Gu DY, Huang HY, Xu Z, Chen JF. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials. World J Gastroenterol 2010; 16: 5889-5894
3. Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15: 4415-4422
4. Malik I, Bernal P, Byrd J. A phase I study of docetaxel, oxaliplatin, & amp; capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer Invest 2010; 28: 833-838
5. Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol 2010; 66: 797-805
6. Farhat FS, Kattan J, Chahine GY, Younes FC, Nasr FL, Mroue RM, Ghosn MG. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer. Med Oncol 2010; 27: 722-727
7. Benson AB. Advanced gastric cancer: an update and future directions. Gastrointest Cancer Res 2008; 2: S47-S53
8. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 2010; 36: 601-606
9. Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, Michel P. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer 2010; 10: 510
10. Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010; 58: 1-40
11. Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A, Tonelli P. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer 2007; 96: 1043-1046
12. Hirata K, Horikoshi N, Tominaga K, Sohma K, Yamaguchi K, Okazaki M, Furuhata T, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Yamamitsu S, Shirasaka T. [Pharmacokinetics of S-1]. Gan To Kagaku Ryoho 2006; 33 Suppl 1: 27-35
13. Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol 2009; 15: 2689-2692
14. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 2010; 21: 1001-1005
15. Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, Lee SS, Jang G, Yoo C, Bae KS, Kang YK. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2010; 65: 473-480
16. Xu GM, Li ZZ. Superior gastrointestinal endoscopics. 1th ed. Shanghai: Shanghai scientific and technical publishers, 2003: 636
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
18. Gao SG, Cheng SC, Feng XS, Chen JM, Dong JT, Wang HY, Wang LD. Microwave tissue coagulation combined with "Savary-Gilliard" rod dilation via endoscopy in the treatment of anastomotic-stenosis after esophageal and/or gastric cardiac cancer operation. Zhongguo Neijing Zazhi 2006; 12: 458-461
19. Sun Y. MD Oncology. 1th ed. Beijing: People's medical publishing house, 2003: 994-995
20. Chrischilles EA, VanGilder R, Wright K, Kelly M, Wallace RB. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. J Am Geriatr Soc 2009; 57: 1000-1006
21. Kadokawa Y, Sonoda K, Nakajima S, Kawabe A, Egawa H. [Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy]. Gan To Kagaku Ryoho 2010; 37: 711-713
22. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 816-820
23. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553
24. Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol 2011; 17: 181-190
25. Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci 2009; 98: 3879-3885
26. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442